In recent years,recombinant human bone morphogenetic protein-2 (rhBMP-2) has been introduced as a therapeutic option in the treatment of several congenital and acquired craniofacial defects.Although there have been promising clinical results,the international literature still lacks complete guidelines,including limits and indications for the use of rhBMP-2.The possible indications for rhBMP-2 in patients undergoing facial trauma are discussed in this article.
展开▼
